Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06589310 · ClinicalTrials.gov registry record
Falcon Real World Evidence Registry
A clinical trial of Cancer, sponsored by Exact Sciences Corporation.
- Recruiting
- Registry status
- 25,000
- Enrollment target
- 2
- Study locations
NCT06589310: Recruiting study of Cancer, sponsored by Exact Sciences Corporation.
NCT06589310 is a study of Cancer that is actively recruiting participants, run by Exact Sciences Corporation. The registered enrollment target is 25,000 participants, above the 3,450-participant average among 615 other Cancer trials with a reported enrollment target (625% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06589310, a study of Cancer, is actively recruiting participants, sponsored by Exact Sciences Corporation.
- RECRUITING
- Registry status
- 25,000 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a multi-site registry of patients receiving the Exact Sciences Multicancer Early Detection (MCED) test.
Primary Outcome
Particpant is alive or deceased
Conditions Studied
Interventions
- DEVICE Exact Sciences Multicancer Early Detection (MCED) Test
Study Locations (2)
Illinois
- Endeavor Health - Evanston
Texas
- Baylor Scott & White Health - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25,000 participants |
| Start Date | 2024-08-01 |
| Est. Completion | 2031-01 |
What NCT06589310 shows while recruiting
NCT06589310 is an observational study that tracks outcomes without assigning an intervention. Its 25,000 participants enrollment target places it among the larger protocols in the corpus, above the 3,450-participant average among 615 other Cancer trials with a reported enrollment target (625% higher).
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Exact Sciences Multicancer Early Detection (MCED) Test is the first listed.
NCT06589310 reports a single indexed study location in Illinois, Texas.
Frequently Asked Questions
What is clinical trial NCT06589310 about?
NCT06589310 is a clinical study titled "Falcon Real World Evidence Registry". This is a multi-site registry of patients receiving the Exact Sciences Multicancer Early Detection (MCED) test.
What is the current status of trial NCT06589310?
This trial is currently recruiting. The enrollment target is 25,000 participants. The study started on 2024-08-01. Estimated completion is 2031-01.
What conditions does trial NCT06589310 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT06589310?
The interventions under investigation include: Exact Sciences Multicancer Early Detection (MCED) Test (DEVICE).
Who is sponsoring clinical trial NCT06589310?
This trial is sponsored by Exact Sciences Corporation, which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06589310 being conducted?
This trial has 2 study locations across Illinois, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06589310's enrollment target sits among peer trials
25,000 15th of 615 higher than 600 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04595201 · 25,000 participants
Clinical Follow-up of Pregnant Subjects Undergoing NIPT
- NCT04994015 · 25,000 participants
Parkinson's Foundation PD GENEration Genetic Registry
- NCT06773897 · 25,000 participants
Rutgers University Study of the Genetics of Breast Cancer.
- NCT06774417 · 25,000 participants · NA
Digital Strategies to Advance Help-Seeking - Aim 3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI